0000950170-23-062204.txt : 20231109 0000950170-23-062204.hdr.sgml : 20231109 20231109170031 ACCESSION NUMBER: 0000950170-23-062204 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tracon Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001394319 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 342037594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36818 FILM NUMBER: 231393544 BUSINESS ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 BUSINESS PHONE: 858-550-0780 MAIL ADDRESS: STREET 1: 4350 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 800 CITY: San Diego STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Tracon Pharmaceuticals Inc DATE OF NAME CHANGE: 20070324 10-Q 1 tcon-20230930.htm 10-Q 10-Q
0001394319--12-31Q3falsehttp://fasb.org/us-gaap/2023#CollaborativeArrangementMemberhttp://fasb.org/us-gaap/2023#CollaborativeArrangementMemberhttp://fasb.org/us-gaap/2023#CollaborativeArrangementMember00013943192023-11-030001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMembertcon:FirstPhaseClinicalTrialMember2023-01-012023-09-300001394319us-gaap:RetainedEarningsMember2022-07-012022-09-300001394319us-gaap:CommonStockMembertcon:EquityPlanMember2022-01-012022-09-300001394319tcon:WarrantsExpirationNovemberFourteenTwoThousandTwentyThreeThroughJuneFourTwoThousandTwentyFourMembertcon:SiliconValleyBankMember2023-09-300001394319us-gaap:RetainedEarningsMember2023-01-012023-03-310001394319us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001394319us-gaap:CommonStockMember2022-12-310001394319us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001394319tcon:SiliconValleyBankMembertcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember2023-09-300001394319tcon:TwoThousandEighteenLoanAndSecurityAgreementMembertcon:SiliconValleyBankMember2018-05-012018-05-310001394319us-gaap:CommonStockMember2023-06-3000013943192023-06-300001394319us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMembertcon:EquityPlanMember2022-01-012022-12-310001394319us-gaap:CommonStockMember2022-06-300001394319us-gaap:RetainedEarningsMember2022-09-3000013943192023-01-012023-09-3000013943192023-07-012023-09-3000013943192022-06-3000013943192023-09-3000013943192023-04-012023-06-3000013943192022-12-310001394319tcon:CapitalOnDemandSalesAgreementMembertcon:JonesTradingInstitutionalServicesLLCMemberus-gaap:CommonStockMember2023-09-300001394319tcon:CommonStockOptionsMember2023-01-012023-09-300001394319us-gaap:CommonStockMember2023-01-012023-09-3000013943192022-01-012022-03-310001394319us-gaap:CommonStockMember2023-04-012023-06-300001394319us-gaap:CommonStockMember2022-01-012022-03-3100013943192021-12-310001394319us-gaap:CommonStockMember2022-04-012022-06-300001394319us-gaap:CommonStockMembertcon:EquityPlanMember2022-01-012022-12-310001394319tcon:RunwayGrowthFinanceCorpLoanAgreementMember2023-09-300001394319us-gaap:CommonStockMember2023-03-310001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMember2018-11-300001394319tcon:WarrantsExpirationMayThreeTwoThousandTwentyFiveMember2023-09-300001394319us-gaap:EmployeeStockMember2023-01-012023-09-300001394319tcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember2023-09-300001394319tcon:WarrantsExpirationMarchTenTwoThousandThirtyThreeMember2023-09-300001394319us-gaap:AdditionalPaidInCapitalMember2022-06-300001394319tcon:CommonStockOptionsMember2022-01-012022-09-300001394319tcon:WarrantsExpirationAugustThirtyOneTwoThousandThirtyMember2023-09-3000013943192022-04-012022-06-300001394319us-gaap:EmployeeStockMember2022-01-012022-09-300001394319tcon:LincolnParkPurchaseAgreementMemberus-gaap:CommonStockMember2023-09-3000013943192022-03-310001394319tcon:WarrantsExpirationMarchTwentySevenTwoThousandTwentyFourMember2023-09-300001394319tcon:TermLoanCMembersrt:MaximumMembertcon:RunwayGrowthFinanceCorpMembertcon:LoanAndSecurityAgreementMember2022-09-300001394319us-gaap:CommonStockMember2021-12-310001394319us-gaap:AdditionalPaidInCapitalMember2022-03-310001394319us-gaap:AdditionalPaidInCapitalMember2023-06-300001394319us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001394319tcon:TermLoanCMembersrt:MaximumMembertcon:RunwayGrowthFinanceCorpMembertcon:LoanAndSecurityAgreementMember2023-04-200001394319us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100013943192022-07-012022-09-300001394319tcon:WarrantsExpirationJuneTwentyOneTwoThousandThirtyTwoMember2023-09-300001394319us-gaap:PrivatePlacementMemberus-gaap:CommonStockMember2023-03-012023-03-310001394319us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001394319us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001394319us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000013943192023-09-012023-09-300001394319us-gaap:EmployeeStockOptionMember2023-01-012023-09-3000013943192022-12-300001394319tcon:WarrantsMembertcon:TermLoanAMembertcon:RunwayGrowthFinanceCorpMember2022-09-300001394319us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001394319tcon:SiliconValleyBankMembertcon:WarrantsExpirationJanuaryTwentyFiveTwoThousandTwentyFourMember2023-09-300001394319us-gaap:CommonStockMember2022-03-310001394319us-gaap:RetainedEarningsMember2023-06-300001394319us-gaap:MoneyMarketFundsMember2022-12-310001394319us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001394319tcon:LincolnParkPurchaseAgreementMember2023-05-312023-05-310001394319tcon:TermLoanCMembersrt:MaximumMembertcon:RunwayGrowthFinanceCorpMembertcon:LoanAndSecurityAgreementMember2023-04-050001394319tcon:WarrantsExpirationNovemberFourteenTwoThousandTwentyThreeThroughJuneFourTwoThousandTwentyFourMember2023-09-300001394319tcon:CommonStockPurchasePriceOfOnePointThreeSevenPerShareMemberus-gaap:PrivatePlacementMemberus-gaap:CommonStockMembertcon:TwentyTwentyThreePreFundedWarrantsMember2023-03-3100013943192022-09-300001394319us-gaap:RetainedEarningsMember2023-03-310001394319us-gaap:RetainedEarningsMember2022-01-012022-03-310001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMembertcon:FirstPhaseTwoClinicalTrialMember2018-11-012018-11-300001394319us-gaap:MoneyMarketFundsMember2023-09-3000013943192022-12-012022-12-3000013943192023-01-012023-03-310001394319tcon:WarrantsExpirationSeptemberTwoTwoThousandThirtyTwoMember2023-09-300001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMembertcon:FirstPhaseClinicalTrialMember2018-11-012018-11-300001394319us-gaap:RetainedEarningsMember2022-03-310001394319us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMembertcon:EquityPlanMember2022-01-012022-09-300001394319us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001394319us-gaap:CommonStockMember2022-01-012022-09-300001394319us-gaap:CommonStockMember2022-09-300001394319us-gaap:RetainedEarningsMember2023-09-300001394319us-gaap:RetainedEarningsMember2021-12-310001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMembertcon:FirstPhaseClinicalTrialMember2023-04-012023-04-300001394319us-gaap:AdditionalPaidInCapitalMember2023-03-310001394319us-gaap:RetainedEarningsMember2023-04-012023-06-300001394319tcon:LincolnParkPurchaseAgreementMemberus-gaap:CommonStockMember2023-01-012023-09-300001394319tcon:LincolnParkPurchaseAgreementMember2023-01-012023-09-3000013943192023-07-012023-07-310001394319us-gaap:RetainedEarningsMember2022-04-012022-06-300001394319tcon:RunwayGrowthFinanceCorpLoanAgreement1Membertcon:LoanAndSecurityAgreementMember2022-09-300001394319tcon:CapitalOnDemandSalesAgreementMembertcon:JonesTradingInstitutionalServicesLLCMemberus-gaap:CommonStockMember2023-01-012023-09-300001394319tcon:TjFourThreeZeroNineAgreementMember2018-11-300001394319us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001394319tcon:RunwayGrowthFinanceCorpLoanAgreement1Membertcon:LoanAndSecurityAgreementMember2022-12-012022-12-300001394319us-gaap:WarrantMember2022-01-012022-09-300001394319us-gaap:CommonStockMember2023-01-012023-03-310001394319us-gaap:PrivatePlacementMemberus-gaap:CommonStockMembertcon:TwentyTwentyThreePreFundedWarrantsMember2023-03-310001394319tcon:TjFourThreeZeroNineAgreementMembertcon:ImabBiopharmaMember2018-11-012018-11-300001394319us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001394319us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001394319us-gaap:AdditionalPaidInCapitalMember2022-12-310001394319us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001394319us-gaap:CommonStockMembertcon:EquityPlanMember2023-07-012023-09-300001394319tcon:BispecificAgreementMembertcon:ImabBiopharmaMember2018-11-012018-11-300001394319tcon:CapitalOnDemandSalesAgreementMemberus-gaap:CommonStockMembertcon:LincolnParkCapitalFundLlcMember2023-09-300001394319us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001394319tcon:RunwayGrowthFinanceCorpLoanAgreement1Membertcon:LoanAndSecurityAgreementMember2023-01-012023-03-310001394319us-gaap:WarrantMember2023-01-012023-09-300001394319us-gaap:PrivatePlacementMemberus-gaap:CommonStockMembertcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember2023-03-310001394319us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001394319us-gaap:ResearchAndDevelopmentArrangementMember2023-09-300001394319us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMembertcon:EquityPlanMember2023-01-012023-09-300001394319us-gaap:AdditionalPaidInCapitalMember2022-09-300001394319us-gaap:AdditionalPaidInCapitalMember2021-12-310001394319us-gaap:CommonStockMember2023-07-012023-09-300001394319srt:MaximumMembertcon:RunwayGrowthFinanceCorpMembertcon:TermLoanBMembertcon:LoanAndSecurityAgreementMember2022-09-300001394319us-gaap:PrivatePlacementMemberus-gaap:CommonStockMembertcon:CommonStockPurchasePriceOfOnePointThreeEightPerShareMember2023-03-012023-03-310001394319tcon:RunwayGrowthFinanceCorpMembertcon:TermLoanMembertcon:LoanAndSecurityAgreementMember2022-09-012022-09-300001394319tcon:LincolnParkPurchaseAgreementMember2023-05-310001394319tcon:TwentyTwentyThreePreFundedWarrantsMember2023-03-012023-03-310001394319us-gaap:RetainedEarningsMember2022-06-3000013943192022-01-012022-09-300001394319us-gaap:AdditionalPaidInCapitalMember2023-09-300001394319us-gaap:RetainedEarningsMember2023-07-012023-09-300001394319us-gaap:CommonStockMembertcon:EquityPlanMember2023-01-012023-09-300001394319tcon:TermLoanAMembertcon:RunwayGrowthFinanceCorpMembertcon:LoanAndSecurityAgreementMember2022-09-3000013943192023-03-310001394319srt:MaximumMembertcon:RunwayGrowthFinanceCorpMembertcon:TermLoanMembertcon:LoanAndSecurityAgreementMember2022-09-300001394319us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001394319us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001394319tcon:RunwayGrowthFinanceCorpLoanAgreement1Membertcon:LoanAndSecurityAgreementMember2023-04-042023-04-050001394319us-gaap:CommonStockMember2022-07-012022-09-300001394319tcon:WarrantsExpirationAugustTwentySevenTwoThousandThirtyMember2023-09-300001394319us-gaap:CommonStockMember2023-09-300001394319us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001394319us-gaap:RetainedEarningsMember2022-12-310001394319tcon:LincolnParkPurchaseAgreementMemberus-gaap:CommonStockMember2023-05-312023-05-310001394319tcon:SiliconValleyBankMember2023-09-30iso4217:USDxbrli:sharesxbrli:puretcon:Antibodyxbrli:sharesiso4217:USDtcon:Tranche

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-36818

 

TRACON Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

34-2037594

(State or other jurisdiction of
incorporation or organization)

 

(IRS Employer
Identification No.)

 

 

 

4350 La Jolla Village Drive, Suite 800,
San Diego CA

 

92122

(Address of principal executive offices)

 

(Zip Code)

(858) 550-0780

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

TCON

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The number of outstanding shares of the registrant’s common stock as of November 3, 2023 was 31,144,335.

 


 

FORM 10-Q

TABLE OF CONTENTS

 

PART I FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Financial Statements

3

 

Condensed Consolidated Balance Sheets

3

 

Unaudited Condensed Consolidated Statements of Operations

4

 

Unaudited Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

5

 

Unaudited Condensed Consolidated Statements of Cash Flows

6

 

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

29

Item 4.

Controls and Procedures

29

 

 

 

PART II OTHER INFORMATION

 

 

 

 

Item 1.

Legal Proceedings

30

Item 1A.

Risk Factors

30

Item 2.

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

63

Item 3.

Defaults Upon Senior Securities

63

Item 4.

Mine Safety Disclosures

64

Item 5.

Other Information

64

Item 6.

Exhibits

65

 

 

 

Signatures

67

 

 

2


 

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TRACON Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

September 30,

 

 

December 31,

 

 

 

 

2023

 

 

2022

 

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

7,763

 

 

$

17,433

 

 

Prepaid and other assets

 

 

577

 

 

 

795

 

 

Total current assets

 

 

8,340

 

 

 

18,228

 

 

Property and equipment, net

 

 

40

 

 

 

51

 

 

Restricted cash

 

 

72

 

 

 

67

 

 

Other assets

 

 

961

 

 

 

1,123

 

 

Total assets

 

$

9,413

 

 

$

19,469

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

10,622

 

 

$

11,107

 

 

Accrued compensation and related expenses

 

 

1,080

 

 

 

1,457

 

 

Long-term debt, current portion

 

 

 

 

 

9,807

 

 

Total current liabilities

 

 

11,702

 

 

 

22,371

 

 

Other long-term liabilities

 

 

795

 

 

 

969

 

 

Arbitration financing payable

 

 

 

 

 

3,280

 

 

Commitments and contingencies (Note 4)

 

 

 

 

 

 

 

Stockholders’ deficit:

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, authorized shares — 10,000,000 at
    September 30, 2023 and December 31, 2022; issued and outstanding
   shares —
none

 

 

 

 

 

 

 

Common stock, $0.001 par value; authorized shares — 60,000,000 and 40,000,000 at
    September 30, 2023 and December 31, 2022, respectively; issued and outstanding shares
   —
31,130,335 and 23,125,250 at September 30, 2023 and December 31, 2022,
   respectively

 

 

31

 

 

 

23

 

 

Additional paid-in capital

 

 

237,823

 

 

 

229,737

 

 

Accumulated deficit

 

 

(240,938

)

 

 

(236,911

)

 

Total stockholders’ deficit

 

 

(3,084

)

 

 

(7,151

)

 

Total liabilities and stockholders’ deficit

 

$

9,413

 

 

$

19,469

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes.

 

3


 

TRACON Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Collaboration revenue

 

$

 

 

$

 

 

$

9,000

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

2,326

 

 

 

4,097

 

 

 

10,783

 

 

 

10,013

 

General and administrative

 

 

1,262

 

 

 

2,280

 

 

 

5,522

 

 

 

12,049

 

Arbitration success fees

 

 

(2,000

)

 

 

 

 

 

2,375

 

 

 

 

Total operating expenses

 

 

1,588

 

 

 

6,377

 

 

 

18,680

 

 

 

22,062

 

Loss from operations

 

 

(1,588

)

 

 

(6,377

)

 

 

(9,680

)

 

 

(22,062

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(646

)

 

 

(58

)

 

 

(7,341

)

 

 

(76

)

Other income, net

 

 

12,997

 

 

 

 

 

 

12,994

 

 

 

 

Total other income (expense)

 

 

12,351

 

 

 

(58

)

 

 

5,653

 

 

 

(76

)

Net income (loss)

 

$

10,763

 

 

$

(6,435

)

 

$

(4,027

)

 

$

(22,138

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.29

 

 

$

(0.30

)

 

$

(0.13

)

 

$

(1.08

)

Diluted

 

$

0.29

 

 

$

(0.30

)

 

$

(0.13

)

 

$

(1.08

)

Weighted-average number of common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

36,770,038

 

 

 

21,469,977

 

 

 

30,462,400

 

 

 

20,455,877

 

Diluted

 

 

36,856,064

 

 

 

21,469,977

 

 

 

30,462,400

 

 

 

20,455,877

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes.

 

4


 

TRACON Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Statements of Stockholders’ (Deficit) Equity

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Stockholders’

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

(Deficit)

 

 

Balance at December 31, 2022

 

 

23,125,250

 

 

$

23

 

 

$

229,737

 

 

$

(236,911

)

 

$

(7,151

)

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

484

 

 

 

 

 

 

484

 

 

Issuance of common stock and warrants, net of offering costs

 

 

902,641

 

 

 

1

 

 

 

4,098

 

 

 

 

 

 

4,099

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,504

)

 

 

(8,504

)

 

Balance at March 31, 2023

 

 

24,027,891

 

 

 

24

 

 

 

234,319

 

 

 

(245,415

)

 

 

(11,072

)

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

502

 

 

 

 

 

 

502

 

 

Issuance of common stock under equity plans

 

 

31,569

 

 

 

 

 

 

43

 

 

 

 

 

 

43

 

 

Issuance of common stock, net of offering costs

 

 

2,570,133

 

 

 

3

 

 

 

1,071

 

 

 

 

 

 

1,074

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,286

)

 

 

(6,286

)

 

Balance at June 30, 2023

 

 

26,629,593

 

 

 

27

 

 

 

235,935

 

 

 

(251,701

)

 

 

(15,739

)

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

493

 

 

 

 

 

 

493

 

 

Issuance of common stock, net of offering costs

 

 

4,500,742

 

 

 

4

 

 

 

1,395

 

 

 

 

 

 

1,399

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

10,763

 

 

 

10,763

 

 

Balance at September 30, 2023

 

 

31,130,335

 

 

$

31

 

 

$

237,823

 

 

$

(240,938

)

 

$

(3,084

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Total

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Stockholders’

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Equity (Deficit)

 

 

Balance at December 31, 2021

 

 

19,445,903

 

 

$

19

 

 

$

219,471

 

 

$

(207,776

)

 

$

11,714

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

548

 

 

 

 

 

 

548

 

 

Issuance of common stock, net of offering costs

 

 

10,389

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon cashless exercise of pre-funded warrants

 

 

170,668

 

 

 

1

 

 

 

 

 

 

 

 

 

1

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(9,473

)

 

 

(9,473

)

 

Balance at March 31, 2022

 

 

19,626,960

 

 

 

20

 

 

 

220,019

 

 

 

(217,249

)

 

 

2,790

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

535

 

 

 

 

 

 

535

 

 

Issuance of common stock under equity plans

 

 

23,461

 

 

 

 

 

 

49

 

 

 

 

 

 

49

 

 

Issuance of common stock and warrants, net of offering costs

 

 

1,771,377

 

 

 

1

 

 

 

5,397

 

 

 

 

 

 

5,398

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,230

)

 

 

(6,230

)

 

Balance at June 30, 2022

 

 

21,421,798

 

 

 

21

 

 

 

226,000

 

 

 

(223,479

)

 

 

2,542

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

481

 

 

 

 

 

 

481

 

 

Issuance of common stock, net of offering costs

 

 

328,126

 

 

 

1

 

 

 

517

 

 

 

 

 

 

518

 

 

Issuance of common stock warrants in connection with debt financing

 

 

 

 

 

 

 

 

259

 

 

 

 

 

 

259

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,435

)

 

 

(6,435

)

 

Balance at September 30, 2022

 

 

21,749,924

 

 

$

22

 

 

$

227,257

 

 

$

(229,914

)

 

$

(2,635

)

 

 

See accompanying notes.

 

5


 

TRACON Pharmaceuticals, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(4,027

)

 

$

(22,138

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Stock-based compensation

 

 

1,479

 

 

 

1,564

 

Depreciation and amortization

 

 

11

 

 

 

12

 

Noncash interest

 

 

88

 

 

 

17

 

Amortization of debt discount

 

 

7,325

 

 

 

15

 

Lease asset amortization and liability accretion, net

 

 

16

 

 

 

47

 

Changes in assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

218

 

 

 

(316

)

Accounts payable and accrued expenses

 

 

(535

)

 

 

(538

)

Accrued compensation and related expenses

 

 

(377

)

 

 

(249

)

Net cash provided by (used in) operating activities

 

 

4,198

 

 

(21,586

)

Cash flows from investing activities

 

 

 

 

 

 

Purchase of property and equipment

 

 

 

 

 

(13

)

Net cash used in investing activities

 

 

 

 

 

(13

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from long-term debt

 

 

 

 

 

9,960

 

Repayment of long-term debt and arbitration financing payable

 

 

(20,500

)

 

 

(1,680

)

Proceeds from sale of common stock and warrants, net of offering costs

 

 

6,594

 

 

 

6,410

 

Proceeds from issuance of common stock under equity plans

 

 

43

 

 

 

49

 

Net cash (used in) provided by financing activities

 

 

(13,863

)

 

14,739

 

Change in cash, cash equivalents, and restricted cash

 

 

(9,665

)

 

(6,860

)

Cash, cash equivalents, and restricted cash at beginning of period

 

 

17,500

 

 

24,072

 

Cash, cash equivalents, and restricted cash at end of period

 

$

7,835

 

 

$

17,212

 

 

 

 

 

 

 

 

 

See accompanying notes.

6


 

TRACON Pharmaceuticals, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

1.
Organization and Summary of Significant Accounting Policies

Organization and Business

TRACON Pharmaceuticals, Inc. (TRACON or the Company) was incorporated in the state of Delaware on October 28, 2004. TRACON is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and utilizes its cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, TRACON Pharma Limited and TRACON Pharma International Limited, which were formed in September 2015 and January 2019, respectively, and are currently inactive. All significant intercompany accounts and transactions have been eliminated.

Basis of Presentation

As of September 30, 2023, the Company has devoted substantially all its efforts to product development, raising capital, and building infrastructure and has not realized revenues from its planned principal operations. The Company has incurred operating losses since inception. As of September 30, 2023, the Company had an accumulated deficit of $240.9 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its product candidates and works to develop additional product candidates through research and development programs. At September 30, 2023, the Company had cash and cash equivalents of $7.8 million, of which $0.1 million is classified as restricted cash as it is pledged as collateral for the Company’s obligations under its corporate headquarters facility lease. The Company’s ability to execute its operating plan through 2024 and beyond depends on its ability to obtain additional funding through equity offerings, debt financings, or potential licensing and collaboration arrangements. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, based on the Company’s current working capital, business plan, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, management believes that there is substantial doubt about its ability to continue as a going concern for a period of 12 months following the date that these unaudited condensed consolidated financial statements are issued. The unaudited condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company plans to continue to fund its losses from operations through its existing cash and cash equivalents, as well as through future equity offerings, debt financings, other third-party funding, and potential licensing or collaboration arrangements. In addition, the Company may fund its losses from operations through the Capital on DemandTM Sales Agreement (the Sales Agreement) the Company entered into with JonesTrading in December 2020, as amended in March 2022, pursuant to which the Company may sell, at its option, up to an aggregate of $50.0 million of the Company’s common stock, $42.9 million of which remained available for sale as of September 30, 2023, and the common stock purchase agreement (the LPC Purchase Agreement) the Company entered into with Lincoln Park Capital Fund, LLC (Lincoln Park) in May 2023, pursuant to which the Company may sell, at its option, up to an aggregate of $26.0 million of the Company’s common stock, $25.0 million of which remained available for sale as of September 30, 2023. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. As a result of adverse macroeconomic and geopolitical developments, such as the ongoing military conflict between Ukraine and Russia or the recent state of war between Israel and Hamas and the related risk of a larger regional conflict, recent and potential future bank failures, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate in the future, it may make any additional debt or equity financing more difficult, more costly, and more dilutive. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans, which could have a material adverse effect on the Company’s business, operating results and financial condition, and the Company’s ability to achieve its intended business objectives. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.

7


 

Unaudited Interim Financial Information

The unaudited condensed consolidated financial statements as of September 30, 2023, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company’s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K filed with the SEC on March 8, 2023.

Use of Estimates

The Company’s unaudited condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue, and expenses. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to expenses incurred for clinical trials. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The carrying amounts approximate fair value due to the short maturities of these investments. Cash and cash equivalents include cash in readily available checking and money market funds.

Restricted Cash

Restricted cash consists of money market funds held by the Company’s financial institution as collateral for the Company’s obligations under its facility lease for the Company’s corporate headquarters in San Diego, California.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.

Property and Equipment

Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful life of the related assets, which is generally five years. Leasehold improvements are amortized over the shorter of the lease term or estimated useful life of the related assets. Repairs and maintenance costs are charged to expense as incurred.

Leases

The Company determines if an arrangement contains a lease at inception. For arrangements where the Company is the lessee, operating leases are recorded as other assets, accounts payable and accrued expenses, and other long-term liabilities within the unaudited condensed consolidated balance sheets. The Company currently does not have any finance leases.

8


 

Operating lease right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as the Company’s leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain that the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term.

Revenue Recognition

To date, substantially all the Company’s revenue has been derived from license and collaboration agreements. The terms of these arrangements included payments to the Company for the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides through its contract manufacturers; and royalties on net sales of licensed products. In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (ASC 606), the Company performs the following five steps in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of these agreements: (i) identification of the contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as, the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. Once a contract is determined to be within the scope of ASC 606, at contract inception the Company assesses the goods or services promised within the contract to determine those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied.

As part of the accounting for these arrangements, the Company develops assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include development timelines, reimbursement rates for personnel costs, discount rates, and probabilities of technical and regulatory success.

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price using the most likely amount method. Performance milestone payments represent a form of variable consideration. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Achievement of milestones that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable until the approvals are achieved. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis and the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.

Manufacturing Supply Services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the outset of the arrangement.

Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its out-licensing arrangements.

9


 

The Company receives payments from its collaborators based on billing schedules established in each contract. Up-front and other payments may require deferral of revenue recognition to a future period until the Company performs its obligations under its collaboration arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Clinical Trial Expense Accruals

As part of the process of preparing the Company’s unaudited condensed consolidated financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with vendors, clinical sites, and consultants in connection with conducting clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts.

The Company’s objective is to reflect the appropriate trial expenses in its unaudited condensed consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with the clinical sites and applicable personnel and outside service providers as to the progress or state of consummation of trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company’s clinical trial accruals are dependent upon accurate reporting by clinical sites and other third-party vendors. Although the Company does not expect its estimates to differ materially from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any particular period. For the three and nine months ended September 30, 2023 and 2022, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.

Research and Development Costs

Research and development costs, including license fees, are expensed as incurred.

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. Net loss and comprehensive loss were the same for all periods presented.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average shares of common stock outstanding for the period, without consideration for common stock equivalents and adjusted for the weighted average number of shares of common stock outstanding that are subject to repurchase. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method.

For the nine months ended September 30, 2023 and for the three and nine months ended September 30, 2022, there is no difference in the weighted-average number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share for those periods because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

 

September 30,

 

 

2023

 

 

2022

 

Warrants to purchase common stock

 

1,534,261

 

 

 

6,987,785

 

Common stock options

 

3,121,152

 

 

 

2,246,310

 

ESPP shares

 

218,825

 

 

 

16,315

 

 

 

4,874,238

 

 

9,250,410

 

 

 

 

 

 

 

 

10


 

For the three months ended September 30, 2023, the weighted-average number of common shares outstanding included in the calculation of basic and diluted EPS are as follows (in common stock equivalent shares):

 

 

Three Months Ended

 

 

September 30, 2023

 

Weighted-average common shares outstanding, basic

 

36,770,038

 

Dilutive securities

 

86,026

 

Weighted-average common shares outstanding, diluted

 

36,856,064

 

Dilutive securities included employee stock purchase plan contributions. Outstanding common stock options and warrants to purchase common stock in the amount of 3,121,152 and 1,534,261, respectively, were excluded from the calculation of diluted EPS under the treasury stock method because to do so would be anti-dilutive.

 

2.
Financial Instruments and Fair Value Measurements

Cash equivalents, which are classified as equity securities, and restricted cash consisted of the following (in thousands):

 

 

 

September 30, 2023

 

 

December 31, 2022

 

 

 

Cost

 

 

Unrealized Gain

 

 

Unrealized (Loss)

 

 

Estimated Fair Value

 

 

Cost

 

 

Unrealized Gain

 

 

Unrealized (Loss)

 

 

Estimated Fair Value

 

Money market funds

 

$

2,300

 

 

$

 

 

$

 

 

$

2,300

 

 

$

10,150

 

 

$

 

 

$

 

 

$

10,150

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Classified as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

$

2,228

 

 

 

 

 

 

 

 

 

 

 

$

10,083

 

Restricted cash

 

 

 

 

 

 

 

 

 

 

 

72

 

 

 

 

 

 

 

 

 

 

 

 

67

 

Total cash equivalents and restricted cash

 

 

 

 

 

 

 

 

 

 

$

2,300

 

 

 

 

 

 

 

 

 

 

 

$

10,150

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At September 30, 2023 and December 31, 2022, the Company had no investments.

The carrying amounts of cash and cash equivalents, prepaid and other assets, accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

Level 1:

Observable inputs such as quoted prices in active markets.

 

 

Level 2:

Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

 

 

Level 3:

Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements.

None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.

11


 

The fair values of the Company’s assets and liabilities, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):

 

 

 

 

 

 

Fair Value Measurements at

 

 

 

 

 

 

Reporting Date Using

 

 

 

 

 

 

Quoted Prices in

 

 

Significant

 

 

 

 

 

 

 

 

 

Active Markets

 

 

Other

 

 

Significant

 

 

 

 

 

 

for Identical

 

 

Observable

 

 

Unobservable

 

 

 

 

 

 

Assets

 

 

Inputs

 

 

Inputs

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

At September 30, 2023